dc.contributor.author
Montesdeoca, Nicolás
dc.contributor.author
López, Marta
dc.contributor.author
Ariza Piquer, Xavier
dc.contributor.author
Herrero Rodríguez, Laura
dc.contributor.author
Makowski, Kamil
dc.date.issued
2020-09-04T10:35:20Z
dc.date.issued
2020-09-04T10:35:20Z
dc.date.issued
2020-09-04T10:35:21Z
dc.identifier
https://hdl.handle.net/2445/170234
dc.description.abstract
Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs. Keywords: cancer drugs; lipid metabolism; lipogenic enzyme inhibitors.
dc.format
application/pdf
dc.publisher
The Federation of American Society of Experimental Biology
dc.relation
Versió preprint del document publicat a: https://doi.org/10.1096/fj.202000705R
dc.relation
The FASEB Journal , 2020, vol. 34, num. 9, p. 11355-11381
dc.relation
https://doi.org/10.1096/fj.202000705R
dc.rights
(c) The Federation of American Society of Experimental Biology, 2020
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Bioquímica i Fisiologia)
dc.subject
Metabolisme dels lípids
dc.subject
Medicaments antineoplàstics
dc.subject
Lipid metabolism
dc.subject
Antineoplastic agents
dc.title
Inhibitors of lipogenic enzymes as a potential therapy against cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/submittedVersion